Amarin (AMRN)
(Delayed Data from NSDQ)
$0.79 USD
0.00 (-0.49%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $0.79 0.00 (0.60%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
AMRN 0.79 0.00(-0.49%)
Will AMRN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AMRN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMRN
Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
AMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates
Other News for AMRN
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
Amarin gets reimbursement approval for Vazkepa in Portugal
Amarin gets reimbursement approval for Vazkepa in Portugal
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)